Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Published:2023-11 Issue:11 Volume:10 Page:e890-e901
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Costa Luciano J,Chhabra Saurabh,Medvedova Eva,Dholaria Bhagirathbhai R,Schmidt Timothy M,Godby Kelly N,Silbermann Rebecca,Dhakal Binod,Bal Susan,Giri Smith,D'Souza Anita,Hall Aric C,Hardwick Pamela,Omel James,Cornell Robert F,Hari Parameswaran,Callander Natalie S

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma;Attal;N Engl J Med,2012

2. Lenalidomide after stem-cell transplantation for multiple myeloma;McCarthy;N Engl J Med,2012

3. Continuous lenalidomide treatment for newly diagnosed multiple myeloma;Palumbo;N Engl J Med,2012

4. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma;Facon;Blood,2018

5. Autologous transplantation and maintenance therapy in multiple myeloma;Palumbo;N Engl J Med,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients;Blood Cancer Journal;2024-09-13

2. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database;Transplantation and Cellular Therapy;2024-09

3. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

4. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma;Cancers;2024-08-23

5. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma;Blood Cancer Journal;2024-08-12